How can we help you?
This webinar, based on PRO labeling of cancer treatment drugs, examines trends in EMA and FDA labeling based on patient-reported outcomes (PROs).
Null hypothesis significance testing is not dead, but in this webinar you will learn why it ought to be.
We'll help you navigate and understand the emerging ISPOR/ISPE Real World Evidence guidelines.
Watch this webinar where our experts discuss different approaches for developing rigorous economic model structures for rare diseases.
For this advanced session on network meta-analysis, listen as our panel of experts discusses some of the recent developments in Bayesian NMA.
In this webinar, we will share design strategies for avoiding selection bias and improving efficiency in observational studies.